Average Mkt Cap
#22 of 49
$15 B
Highest CAGR
#2 of 49
30 %
Immunotherapy can cause autoimmune side effects, where the immune system attacks healthy cells and tissues. Despite the risks, immunotherapy has been shown to be effective in treating some types of cancer. Immunotherapy is also being explored as a potential treatment for autoimmune disorders like multiple sclerosis and rheumatoid arthritis.
0 FDA approvals in Immunotherapy
Investor sentiment
MarketWatchJune 2021
"...The global cancer immunotherapy market is expected to grow at a CAGR of 10.6% during the forecast period 2021-2026, driven by the increasing prevalence of cancer, the growing adoption of immunotherapy treatments, and the expanding research and development activities in this field."
ResearchAndMarketsApril 2021
"...The global cancer immunotherapy market is expected to reach $119.39 billion by 2026, driven by the increasing incidence of cancer, the growing demand for effective and safe immunotherapies, and the increasing availability of targeted and combination therapies."
Sector leaders
Merck & Co.
Merck's Keytruda therapy is expected to generate annual sales of $22 billion by 2025. The therapy was approved for more than 20 different types of cancer, including lung, skin, head and neck, and bladder cancer.
Bristol-Myers Squibb
Bristol-Myers Squibb's Opdivo is a blockbuster immunotherapy drug used to treat multiple cancers, including non-small cell lung cancer, melanoma, and bladder cancer.
Novartis
Novartis developed Kymriah, a CAR-T cell therapy that is used to treat certain types of leukemia and lymphoma. The therapy was the first CAR-T cell therapy to receive FDA approval and has shown promising results in clinical trials.
